fda warning compounded semaglutide safety 2024 2025 Societies take stand against off-brand GLP-1s over concerns Semaglutide Patient Safety Updates |

This is a different approach and the early outcomes being studied are strong enough to make experts curious about whether the triple mechanism can translate into meaningful real-world benefits once larger trials confirm safety and long-term results

That said, contact a healthcare provider at any time, even before the three-month mark, if you are experiencing intolerable side effects like abdominal pain, chronic diarrhea, constipation, or nausea

Pharmaceutical giant Eli Lilly saw its stock jump Thursday morning after announcing initial Phase 3 trial results on orforglipron, a highly anticipated medication for diabetes and weight loss

However, because it does not have MHRA approval , it cannot be sold or supplied for human use outside of regulated clinical trials